Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (71)	3/26/2001 12:27:04 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 222

<So is Bexxar 'death' a certainty?> I would not go that far, but it is probably fair to say that this new 6-18 month delay seriously affects its commercial prospects. More so if Zevalin makes it to the market before Bexxar, as it seems likely to be the case given what we know so far. Now, that was painful to write; remember that 6-12 month lead for Bexxar? The IMMU/AMGN anti-CD22 programs are also moving forward. CRXA may well end up having a drug, but not necessarily a product, defined as an item generating sales of >$150M/year. PB